Armistice Capital’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Armistice Capital’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-603,000	Closed	-$507K	–	277
2023 Q1	$507K	Sell	603,000 -327,000	-35%	-$465K	0.01%	158
2022 Q4	$1.32M	Buy	+930,000	New	+$1.54M	0.02%	123
2021 Q1	–	Sell	-100,000	Closed	-$435K	–	134
2020 Q4	$435K	Buy	+100,000	New	+$469K	0.01%	104

Other funds holding CYTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Armistice Capital's CYTH Position: Q2 2023 in Review

Armistice Capital sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q2 2023, closing a stake of 603,000 shares — an estimated $507K sold.

Armistice Capital first reported a position in CYTH in Q4 2020 and held it in 3 quarters. The position peaked at $1.32M in Q4 2022. 14 funds tracked by Wall St. Rank hold CYTH as of Q2 2023.

Armistice Capital reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Armistice Capital sold 603,000 Cyclo Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $507K.
Armistice Capital first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Armistice Capital's Cyclo Therapeutics, Inc. Common Stock position peaked at $1.32M in Q4 2022.
14 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Armistice Capital's 13F filing for Q2 2023, filed 14 Aug 2023.